Los Angeles Capital Management LLC Purchases 8,523 Shares of OraSure Technologies, Inc. (NASDAQ:OSUR)

Los Angeles Capital Management LLC grew its position in OraSure Technologies, Inc. (NASDAQ:OSUR) by 2.6% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 341,125 shares of the medical instruments supplier’s stock after acquiring an additional 8,523 shares during the quarter. Los Angeles Capital Management LLC owned 0.45% of OraSure Technologies worth $2,098,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Pacer Advisors Inc. increased its stake in OraSure Technologies by 122.5% in the 4th quarter. Pacer Advisors Inc. now owns 2,403,333 shares of the medical instruments supplier’s stock worth $19,707,000 after acquiring an additional 1,323,197 shares during the last quarter. Deutsche Bank AG increased its position in shares of OraSure Technologies by 3.1% during the 3rd quarter. Deutsche Bank AG now owns 196,468 shares of the medical instruments supplier’s stock valued at $1,165,000 after purchasing an additional 5,875 shares during the last quarter. Vanguard Group Inc. increased its position in shares of OraSure Technologies by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 5,396,285 shares of the medical instruments supplier’s stock valued at $32,000,000 after purchasing an additional 64,367 shares during the last quarter. Trexquant Investment LP increased its position in shares of OraSure Technologies by 155.6% during the 4th quarter. Trexquant Investment LP now owns 165,201 shares of the medical instruments supplier’s stock valued at $1,355,000 after purchasing an additional 100,557 shares during the last quarter. Finally, Baader Bank Aktiengesellschaft bought a new position in shares of OraSure Technologies during the 4th quarter valued at approximately $115,000. Institutional investors own 93.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on OSUR. StockNews.com downgraded OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Thursday, May 9th. JPMorgan Chase & Co. cut their target price on OraSure Technologies from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Monday, May 13th. Finally, Evercore ISI cut their target price on OraSure Technologies from $7.00 to $6.50 and set an “in-line” rating on the stock in a research report on Thursday, April 4th. Three equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $6.63.

OraSure Technologies Stock Down 3.1 %

Shares of OraSure Technologies stock opened at $4.40 on Friday. The stock’s fifty day moving average is $4.98 and its two-hundred day moving average is $6.44. The company has a market capitalization of $325.42 million, a PE ratio of 14.67 and a beta of 0.14. OraSure Technologies, Inc. has a 52 week low of $4.11 and a 52 week high of $8.45.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings data on Wednesday, May 8th. The medical instruments supplier reported $0.04 EPS for the quarter, meeting the consensus estimate of $0.04. The company had revenue of $54.10 million for the quarter, compared to the consensus estimate of $52.27 million. OraSure Technologies had a return on equity of 7.68% and a net margin of 7.50%. OraSure Technologies’s quarterly revenue was down 65.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.37 EPS. As a group, research analysts anticipate that OraSure Technologies, Inc. will post -0.08 earnings per share for the current year.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.